Skip to main content

Advertisement

SpringerLink
Log in

Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The Results of Three Year Retrospective Analysis

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Lung cancer is a heterogeneous group of disease and mutational profiling of lung adenocarcinomas is a routine practice in thoracic oncology. Kirsten-RAS (KRAS) and EGFR mutations play an important role in the carcinogenesis of a subset of lung adenocarcinomas. Our aim was to investigate the correlation between bone metastases and EGFR and KRAS mutation status in lung adenocarcinoma patients. Retrospectively we analysed 224 patients with recurrent or metastatic lung adenocarcinomas. Patients were treated with standard chemotherapy as first line therapy and with EGFR-TK inhibitors as a second or third line therapy. 72 of 224 patients (32 %) had verified bone metastases. Bone metastases and Skeletal Related Events (SRE) were more frequent in men, heavy smokers and without treatment of EGFR TK inhibitors. We have found that EGFR and KRAS mutation status are both predictive factors for the treatment efficacy and prognostic factors for the disease progression. However there were no significant correlation between mutation status and the presence of bone metastases (P = 0, 59). In our study the presence of bone metastases proved to be an independent prognostic factor related to poor performance status and worse Quality of Life (QL).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y (2009) Cancer statistic, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR (2011) International Association for the Study of Lung Cancer /American Thoracic Society / European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:2244–2285

    Google Scholar 

  3. Oxnard GR, Binder A, Jänne PA (2013) New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31:1097–1104

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  5. NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617–4625

    Article  PubMed Central  Google Scholar 

  6. Azolli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 36:6251–6266

    Article  Google Scholar 

  7. Paz-Ares L (2012) PARAMOUNT final overall survival (OS) result of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediatly following induction treatment with pem plus cisplatin (cis) for advanced nonsquamosus (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 30:(Suppl, abstr LBA 7507)

  8. Gazdar AF (2009) Activating and resistance mutations of EGFR in nonsmall- cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1):S24–S31

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Fukuoka M, Wu Y (2011) Biomarker Analyses and Final Overall Survival results From a Phase III, randomised, open an label, First-line Study of Gefitinib versus carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874

    Article  CAS  PubMed  Google Scholar 

  10. Bittner N, Ostoros G, Geczi L (2014) New treatment options for lung adenocarcinoma- in view of molecular background. Pathol Oncol Res 20:11–25

    Article  CAS  PubMed  Google Scholar 

  11. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529

    Article  CAS  PubMed  Google Scholar 

  12. Alice Tsang S, Mehra R (2013) Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 31

  13. Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J (2006) Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 1:571–576

    Article  PubMed  Google Scholar 

  14. Sun JM, Ahn JS, Lee S, Kim JA, Lee J (2011) Predictors of skeletalrelated events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71:89–93

    Article  PubMed  Google Scholar 

  15. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6:28–31

    Article  PubMed Central  PubMed  Google Scholar 

  16. Roberts PJ, Stinchcombe TE (2013) KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31:1112–1121

    Article  CAS  PubMed  Google Scholar 

  17. Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T (2014) Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer 50:1819–1828

    Article  CAS  PubMed  Google Scholar 

  18. Normanno N, Luca D, Aldinucci D, Maiello MR, Mancino M (2005) Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 12:471–482

    Article  CAS  PubMed  Google Scholar 

  19. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23:1882–1894

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Nagata M, Kudoh S, Mitsuoka S, Suzumura T, Umekawa K (2013) Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Osaka City Med J 59:45–52

    PubMed  Google Scholar 

  21. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC (2012) Prognostic factor for non-small cell lung cancer with bone metastases at the time of diagnosis. Letters to the editor. Lung Cancer 78:167–170

    Article  Google Scholar 

Download references

Acknowledgments

Many thanks for the National Institute of Oncology Budapest, and the Medical University Pecs, approved this retrospective analysis.

Conflict of Interest

The Authors declare that they have no known conflict of interest with respect to the authorship and/or publication of this article.

Author information

Authors and Affiliations

  1. National Institute of Oncology, Budapest, Hungary

    Nóra Bittner, Erika Tóth, Miklós Kásler & Lajos Géczi

  2. Faculty of Medicine, Department of Pulmonology, University of Pécs, Pécs, Hungary

    Zoltán Balikó, Veronika Sárosi & Terézia László

Authors
  1. Nóra Bittner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zoltán Balikó
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Veronika Sárosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Terézia László
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erika Tóth
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miklós Kásler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lajos Géczi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nóra Bittner.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bittner, N., Balikó, Z., Sárosi, V. et al. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The Results of Three Year Retrospective Analysis. Pathol. Oncol. Res. 21, 1217–1221 (2015). https://doi.org/10.1007/s12253-015-9955-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-015-9955-2

Keywords

Search

Navigation